Anti-hypertensive Treatment in Peripheral Artery Disease

Δημοσίευση στις Apr 2018 στο PubMed: https://pubmed.ncbi.nlm.nih.gov/29459079/?from_term=tsioufis&from_sort=date&from_size=200&from_pos=114

Curr Opin Pharmacol
Actions
Search in PubMed

Search in NLM Catalog

Add to Search

Review

Apr 2018

Affiliations

¹ First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece. Electronic address: [email protected]
² First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.
³ First Department of Propaedeutic Surgery, University of Athens Medical School, Hippocration Hospital, Athens, Greece.

Item in Clipboard

Review

Costas Tsioufis et al.

Curr Opin Pharmacol.

Apr 2018

Affiliations

¹ First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece. Electronic address: [email protected]
² First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.
³ First Department of Propaedeutic Surgery, University of Athens Medical School, Hippocration Hospital, Athens, Greece.

Item in Clipboard

Abstract

Peripheral artery disease (PAD) affects more than 200 million people worldwide. Hypertension has been related to increased risk of PAD. The treatment of elevated blood pressure (BP) in these patients is indicated to lower the cardiovascular risk with a BP goal of less than 130/80mmHg. Although there is no evidence that one class of antihypertensive medication or strategy is superior for BP lowering in PAD, the use of renin-angiotensin-system (RAS) inhibitors can be effective to reduce the cardiovascular risk. Beta-blockers (BBs) are not contraindicated. In the presence of carotid atherosclerosis, calcium-channel blockers (CCBs) and angiotensin-converting-enzyme inhibitors are recommended. In fibromuscular dysplasia the treatment of choice is percutaneous renal angioplasty. In renal artery disease optimal medical therapy includes RAS inhibitors, CCBs, BBs and diuretics.

Cited by
1
PubMed Central articles

Inhibitors of G12C Mutant Ras Proteins for the Treatment of Cancers.

Kargbo RB.
Kargbo RB.
ACS Med Chem Lett. 2018 Dec 10;10(1):10-11. doi: 10.1021/acsmedchemlett.8b00576. eCollection 2019 Jan 10.
ACS Med Chem Lett. 2018.
PMID: 30655937
Free PMC article.

No abstract available..

MeSH terms

Substances

Κωνσταντίνος Τσιούφης

Ο Κωνσταντίνος Τσιούφης είναι Καθηγητής Καρδιολογίας στο Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών. Απόφοιτος του ’87 με βαθμό “ΑΡΙΣΤΑ”, εργάζεται στο Ιπποκράτειο Γενικό Νοσοκομείο Αθηνών με τα κύρια αντικείμενα ενασχόλησής του να είναι η υπέρταση και η επεμβατική καρδιολογία.

See author's posts